AHA 2018 Treatment with icosapent ethyl yielded a strong reduction in CV events in statin-treated patients at high CV risk and residual TG burden. Prof. Stroes considers what we can conclude about how this benefit is achieved.

AHA 2018 Lp(a) is a highly prevalent risk factor, with to date no therapy to lower its levels. A phase 2b study now shows that an antisense oligonucleotide potently lowers production of Lp(a), to optimal levels.

AHA 2018 Adm. Giroir emphasizes the importance for anyone of being physically active, and how recommended levels can easily be achieved. This is important for individual health, but also for national security.

AHA 2018 In PEGASUS-TIMI 54, a patient selection strategy identified a subgroup of patients who may benefit more from long-term treatment with ticagrelor and aspirin, with lower bleeding risk.

AHA 2018 In the EMPA-HEART Cardiolink-6 trial, 6 months of treatment with empagliflozin reduced LV mass, which may contribute to CV benefits seen in SGLT2i outcome trials.

AHA 2018 VITAL evaluated both vitamin D and omega-3 supplementation and found no significant effect on the primary cancer and CV endpoints. Secundary analyses suggested fewer total MI with omega-3 supplementation.

AHA 2018 Based on the PIONEER-HF results, Larry Allen will now confidently start guideline-recommended therapy in-hospital, for patients with acutely decompensated heart failure.

AHA 2018 Yoga-CaRe as replacement for cardiac rehabilitation did not improve CV endpoints in a large randomized trial, but did improve QoL and return to pre-infarct daily activities.

AHA 2018 Deepak Bhatt considers the compounds that were tested in the VITAL and REDUCE-IT trials, which yielded neutral and very positive results, respectively, and what likely caused this discrepancy.

AHA 2018 Little was known about the safety of sacubitril-valsartan in acute heart failure. PIONEER-HF addressed this question and found use of the ARNI to be safe and to lower NT-proBNP.

AHA 2018 U.S. Department of Health & Human Services and AHA teamed up to engage entire communities to be more physically active, by highlighting the evidence that shows that health will benefit from it.

AHA 2018 Post-hoc analyses of the ODYSSEY OUTCOMES trial showed reduced all-cause mortality with alirocumab vs statins in patients with ACS, especially in those with LDL-c of ≥100 mg/dL at baseline.